Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda with Herceptin and chemotherapy in HER2+ esophagogastric cancer
NCT02954536Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2016
- Primary completion
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in esophageal adenocarcinoma (EAC), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Nov 2016; status: completed.
02
Drugs
03
Conditions
esophageal adenocarcinoma (EAC)gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02954536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02954536.